Results 11 to 20 of about 286,663 (309)
Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2015 The therapeutic strategy of non-small cell lung cancer (NSCLC) is dramatically changed with the introduction of molecular targeted drugs in the last years, resulting in a series of results in histologic and molecular level. The discovery of epidermal growth factor receptor (EGFR) mutation, Kirsten rat sarcoma (KRAS) viral oncogene mutation and ...
Kun ZHANG, Hong WANG
openaire +4 more sources
Фармакоэкономика, 2023 Objective: to evaluate the clinical and economic effectiveness of alectinib in comparison with lorlatinib in adult patients with advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC).Materials and methods. The calculations
A. S. Kolbin +3 more
doaj +1 more source
Effect of using different co-ligands during 99mTc-labeling of J18 peptide on SK-MES-1 cell binding and tumor targeting [PDF]
Iranian Journal of Basic Medical Sciences, 2021 Objective(s): Lung cancer is the main cause of cancer death, and its incidence is increasing worldwide. The goal of this study is to evaluate in vitro and in vivo tumor targeting behavior of [99mTc]Tc -HYNIC-(Ser)3-J18 in lung carcinoma (SK-MES-1 ...
Seyed Jalal Hosseinimehr +3 more
doaj +1 more source
Focus on Nivolumab in NSCLC [PDF]
Frontiers in Medicine, 2016 Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issues.
Cortinovis D. L. +4 more
openaire +3 more sources
Сибирский онкологический журнал, 2023 Aim of the study: to evaluate prognostic value of baseline lung immune prognostic index (LIPI) and its modification (mLIPI) for metastatic non-small cell lung cancer (mNSCLC) patients treated with immune checkpoint inhibitors (ICI).Material and methods ...
D. I. Yudin +4 more
doaj +1 more source
Lung Cancer Management, 2016 In the era of high-throughput molecular screening and personalized medicine, difficulty in determining whether cancer mutations are truly 'actionable' remains a gray zone in NSCLC. The most important prerequisite to perform such investigations is the tumor tissue retrieval via biopsy at diagnosis and after occurrence of resistance.
Trombetta, D. +3 more
openaire +2 more sources
Frontiers in Oncology, 2012 The phosphatidylinositol 3-kinases (PI3Ks) are members of a family of intracellular lipid kinases that phosphorylate the 3'-hydroxyl group of phosphatidylinositol and phosphoinositides. PI3K regulate signaling pathways for neoplasia, including cell proliferation, adhesion, survival, and motility.
Martinez-Martí, Alex, Felip, Enriqueta
openaire +3 more sources
Cancer Cell International, 2020 Background Our previous clinical study has shown that Chinese herbal medicine (CHM) Fuzheng Kang-Ai (FZKA) decoction is effective in treating advanced lung cancer patients through prolonging the drug resistance to Gefitinib (GFTN).
Sumei Wang +5 more
doaj +1 more source
OncoImmunology, 2021 Immune checkpoint inhibitors (ICIs) have improved the survival of patients with non-small cell lung cancer (NSCLC) by reinvigorating tumor-specific T cell responses.
Fiamma Berner +30 more
doaj +1 more source
How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
Drugs in Context, 2022 Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating KRAS mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is the most common KRAS ...
Biagio Ricciuti +10 more
doaj +1 more source